Internal Medicine, Hematology & Oncology · Mount Juliet, TN
NPI
1356879795
Since 2017
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
121 Bear Xing Ste 200
Mount Juliet, TN, 37122
Phone (615) 871-9996
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
121,182 services
Medicare patients, 2024
501
Average age 75
Drug cost, 2024
$1.6M
625 prescriptions
Company payments, 2025
$3,770
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Revathi Kollipara was code J1439 (injection, ferric carboxymaltose, 1 mg), 54,750 times for 46 patients. In total Revathi Kollipara billed 121,182 services in 149 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 54,750 | 46 | $0.87 | $47K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 7,000 | 14 | $2.27 | $16K |
| J0897 Injection, denosumab, 1 mg | Office | 4,740 | 44 | $19.72 | $93K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,300 | 33 | $15.88 | $52K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 1,740 | 11 | $36.91 | $64K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,499 | 38 | $0.09 | $132 |
| 85025 Blood Count | Office | 735 | 233 | $7.59 | $5,577 |
| 36415 Venipuncture Blood Collection | Office | 664 | 241 | $8.63 | $5,727 |
| 80053 Clinical Chemistry | Office | 566 | 228 | $10.34 | $5,851 |
| 99214 Office E&M - Established | Office | 286 | 179 | $82.31 | $24K |
| 96367 Intravenous Infusion, Hydration | Office | 240 | 34 | $19.64 | $4,713 |
| 82784 Immunoassay | Office | 229 | 37 | $9.11 | $2,087 |
| 83550 Clinical Chemistry | Office | 223 | 123 | $8.54 | $1,905 |
| 83540 Clinical Chemistry | Office | 223 | 123 | $6.32 | $1,409 |
| 82728 Clinical Chemistry | Office | 221 | 121 | $13.32 | $2,943 |
By year: 2023 $186K for 17,795 services; 2024 $1.2M for 121,182 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 735 | 233 | $7.59 | $5,577 |
| 36415 Venipuncture Blood Collection | 664 | 241 | $8.63 | $5,727 |
| 80053 Clinical Chemistry | 566 | 228 | $10.34 | $5,851 |
| 82784 Immunoassay | 229 | 37 | $9.11 | $2,087 |
| 83540 Clinical Chemistry | 223 | 123 | $6.32 | $1,409 |
| 83550 Clinical Chemistry | 223 | 123 | $8.54 | $1,905 |
| 82728 Clinical Chemistry | 221 | 121 | $13.32 | $2,943 |
| 82607 Clinical Chemistry | 160 | 111 | $14.78 | $2,365 |
| 82746 Clinical Chemistry | 156 | 108 | $14.41 | $2,248 |
| 83521 Immunoassay | 140 | 32 | $16.93 | $2,370 |
Medicare prescription drug claims, 2024
In 2024, the drug Revathi Kollipara prescribed most often to Medicare patients was Anastrozole, with 158 prescriptions and refills. In total Revathi Kollipara wrote 625 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 158 | 412 | 53 | $2,852 |
| Dexamethasone Generic | 32 | 32 | 11 | $457 |
| Prochlorperazine Maleate Generic | 32 | 32 | 22 | $335 |
| Ondansetron Odt Ondansetron | 25 | 25 | 16 | $259 |
| Gabapentin Generic | 24 | 25 | Under 11 | $113 |
| Eliquis Apixaban | 23 | 31 | Under 11 | $17K |
| Promacta Eltrombopag Olamine | 22 | 22 | Under 11 | $161K |
| Letrozole Generic | 20 | 52 | Under 11 | $438 |
| Tamoxifen Citrate Generic | 19 | 55 | Under 11 | $626 |
| Xpovio Selinexor | 16 | 16 | Under 11 | $434K |
| Ondansetron Hcl Generic | 15 | 15 | Under 11 | $55.23 |
| Xarelto Rivaroxaban | 15 | 31 | Under 11 | $17K |
| Levothyroxine Sodium Generic | 15 | 32 | Under 11 | $193 |
| Olanzapine Generic | 14 | 24 | Under 11 | $139 |
| Folic Acid Generic | 14 | 32 | Under 11 | $56.85 |
Brand drugs: 155 claims; generic drugs: 470 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Revathi Kollipara $3,770 ($3,770 in general payments such as food, travel and fees) from 41 companies. The largest payer was Novartis Pharmaceuticals Corporation with $404.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 18 | $404 |
| Daiichi Sankyo Inc. 4568.T | 10 | $373 |
| Merck Sharp & Dohme LLC MRK | 12 | $329 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $302 |
| Genzyme Corporation SNY | 4 | $219 |
| Pfizer Inc. PFE | 12 | $199 |
| Adc Therapeutics America, Inc. | 3 | $165 |
| Incyte Corporation INCY | 8 | $144 |
| Stemline Therapeutics Inc. | 2 | $144 |
| Eisai Inc. 4523.T | 6 | $137 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.